Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 19/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606327 | 0.85 | KMT2A (0.57) | CCR3CYP2D6MEN1KMT2A | |
| SCHEMBL4872856 | 0.83 | CCR3 (0.55) | CCR3CYP2D6MEN1KMT2A | |
| SCHEMBL4606996 | 0.83 | CCR3 (0.68) | CCR3CYP2D6 | |
| SCHEMBL4603686 | 0.81 | CCR3 (0.65) | CCR3CYP2D6 | |
| SCHEMBL4605707 | 0.81 | CCR3 (0.54) | CCR3CYP2D6 | |
| SCHEMBL27589483 | 0.80 | CCR3 (0.53) | CCR3CYP2D6 | |
| Hydrochloric Acid SCHEMBL4606314 | 0.80 | CCR3 (0.48) | CCR3CYP2D6 | |
| SCHEMBL4608149 | 0.79 | CCR3 (0.66) | CCR3CYP2D6 | |
| SCHEMBL4603383 | 0.79 | CCR3 (0.57) | CCR3CYP2D6 | |
| SCHEMBL4604783 | 0.79 | CCR3 (0.56) | CCR3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | CCR3 1/4885CYP2D6 2500/4885MEN1 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.